A 56-year-old man is diagnosed with the metabolic syndrome, which consists of hypertension, insulin resistance, dyslipidemia, and abdominal obesity. He has no prior history of cardiac or vascular disease and is otherwise well. His fasting T-chol is 270 mg/dL, HDL 50 mg/dL, LDL 150 mg/dL, and triglycerides 150 mg/dL. His Framingham risk calculation approximates a 10- year risk for cardiac events of 10%-20%.For the above patient with dyslipidemia, select the most appropriate treatment.
A 56-year-old man is diagnosed with the metabolic syndrome, which consists of hypertension, insulin resistance, dyslipidemia, and abdominal obesity. He has no prior history of cardiac or vascular disease and is otherwise well. His fasting T-chol is 270 mg/dL, HDL 50 mg/dL, LDL 150 mg/dL, and triglycerides 150 mg/dL. His Framingham risk calculation approximates a 10- year risk for cardiac events of 10%-20%.For the above patient with dyslipidemia, select the most appropriate treatment.
💡 Explanation
**Question:** A 56-year-old man is diagnosed with the **metabolic syndrome**, which consists of hypertension, insulin resistance, dyslipidemia, and abdominal obesity. He has no prior history of cardiac or vascular disease and is otherwise well. His fasting T-chol is 270 mg/dL, HDL 50 mg/dL, LDL 150 mg/dL, and triglycerides 150 mg/dL. His Framingham risk calculation approximates a 10-year risk for cardiac events of 10%-20%. For the above patient with dyslipidemia, select the most appropriate treatment.
A. Lifestyle modifications
B. Statins
C. Angiotensin-converting enzyme inhibitors (ACEi)
D. Sodium-glucose co-transporter 2 inhibitors (SGLT2i)
**Correct Answer:** B. Statins
**Core Concept:** Dyslipidemia is a condition characterized by abnormal lipid levels in the blood, leading to increased risk of cardiovascular events. It is a key component of the **metabolic syndrome**, which includes hypertension, insulin resistance, and abdominal obesity. Dyslipidemia is defined as:
Statins are a class of medications that primarily target the **liver** and reduce cholesterol production. They are a **first-line treatment** for dyslipidemia, particularly in patients with the **metabolic syndrome** and increased cardiovascular risk. Statins primarily work by inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver. This leads to a decrease in LDL cholesterol levels, making statins an effective choice for managing dyslipidemia and reducing cardiovascular risk in patients with the **metabolic syndrome**.
**Why Other Options are Incorrect:**
**A. Lifestyle modifications**: While these are essential components of managing dyslipidemia and the **metabolic syndrome**, they alone may not be sufficient to achieve optimal lipid levels and reduce cardiovascular risk.
**C. Angiotensin-converting enzyme inhibitors (ACEi)** are primarily used for hypertension management. While they may have a slight impact on lipid profile, they are not the primary treatment for dyslipidemia.
**D. Sodium-glucose co-transporter 2 inhibitors (SGLT2i)** are primarily used for type 2 diabetes management. While they may have a slight impact on lipid profile, they are not the primary treatment for dyslipidemia.
**Clinical Pearl:** In patients with the **metabolic syndrome** and elevated cardiovascular risk, statins should be considered as the primary treatment for dyslipidemia management. Lifestyle modifications and medications targeting other comorbidities (such as ACE inhibitors and SGLT2 inhibitors) may also be involved in the management of dyslipidemia, but statins are the primary treatment option.
✓ Correct Answer: D. hepatic hydroxymethylglutaryl coenzyme A (HMG-Co) reductase inhibitors (lovastatin, simvastatin, pravastatin)
📤 Share this MCQ
Share Card Preview
👆 1080x1080 square card — fills the full width in WhatsApp and Telegram